Short Answer

Natera is expected to process above 1,075,000 tests in Q3 2026, an outcome the market prices at 69.0% but which would contradict management's explicit guidance that the quarter would not set a new overall volume record; the model prices this at 38.6%.

1. Market Behavior & Drivers

This market has registered no price movement, holding at a constant 69.0% probability since its first available data point. Zero contracts have been traded over the period, indicating a complete lack of price-setting activity. As there have been no market movements, there are no price changes to attribute to external events or news.
The static 69.0% price appears to be an initial assessment based on Natera's most recently reported metrics. For Q2 2026, the company processed 1,043,900 tests, a volume that already exceeds the market's resolution threshold of 1,025,000 for Q3. This performance, coupled with a reported 22.4% year-over-year growth in total test volume in Q2, provides a fundamental basis for the positive probability. Without any trading activity, however, this price level reflects an untested opening sentiment rather than an evolving market consensus.
  • Since last update (~12h): For 'Above 1025000', the model probability surged +58.6pp, widening the edge as market held steady.
  • The model's probability for 'Above 1075000' rose +38.6pp, compressing the edge as market remained at 69.0%.
  • Headline model probability rose +38.6pp, yet market climbed +69.0pp, widening the overall edge to -30.4pp.
  • The model anticipates volumes above 1,025,000, but below Q2's record.
  • Market expects volumes above 1,075,000, contradicting explicit management guidance.
  • Medicare LCD changes and Oncology growth may provide upward volume support.

Current Context

Natera had not reported Q3 2026 results as of October 24, 2026, with Q2 2026 serving as the latest actual quarter. For Q2 2026, which ended June 30 and was reported August 6, Natera processed 1,043,900 tests (+22.4% year over year), including 296,700 oncology tests (+57.2%) [1][2]. Q2 financials showed $752.8 million in revenue (+37.7% year over year), a gross margin of 64.5%, an operating loss of $75.8 million, and a GAAP net loss of $67.0 million or $0.47 per diluted share [1]. Cash, equivalents, and restricted cash increased by approximately $3.6 million [1]. Management raised FY2026 revenue guidance by $100 million at the midpoint to $2.85–$2.91 billion, targeting approximately 64%–66% gross margin and positive full-year cash flow; this revenue outlook implied roughly 31% growth excluding true-ups [1][2]. Management stated it did not expect a new overall volume record in Q3 2026, noting that Q2’s record benefited from recovery after Q1 weather disruptions [1][2].
Q3 2026 expectations reflect management caution and diverse analyst estimates. Published analyst estimates for Q3 revenue range from roughly $707.5–$719.0 million, with EPS estimates between negative $0.22 to negative $0.28 [3][4][5][6]. These estimates imply approximately 19.5%–21.4% year-over-year revenue growth but a sequential decline from Q2 [3][4][5][6]. A market-style forecast cited by OctagonAI indicates "Above 1,025,000 tests," using Q2’s 1,043,900 as a benchmark, though this is an informal forecast, not an announced company result, and acknowledges management’s "no new record" signal for Q3 [7][8]. The Q3 2026 earnings date was not officially confirmed as of October 24, but trackers clustered around November 5–11, with November 5 aligned with Natera’s historical Thursday-after-close reporting pattern [7][8][3][4][6].
Operational developments and analyst sentiment frame Natera's near-term outlook. Key developments to monitor include Signatera clinical-MRD adoption and average selling price (ASP) progression, women’s-health products such as enhanced Panorama and Fetal Focus, organ-health reimbursement following a Medicare local coverage determination effective August 30, and potential Signatera commercialization in Japan [9][2][10]. Expert and analyst sentiment was broadly constructive but valuation-sensitive; MarketWatch showed a Buy consensus from 26 ratings with a $344.33 average target, while FrontierPicks suggested limited upside given strong growth and a significant prior share-price run, absent a material beat on Q3 guidance or durable volume/ASP improvement [9][6].
Sources (10)
  1. 1Natera, Inc. | Natera Reports Second Quarter 2026 Financial Resultsinvestor.natera.com
  2. 2Earnings call transcript: Natera tops revenue view in Q2 2026, shares jump after hours By Investing.cominvesting.com
  3. 3Natera Q3 2026 Earnings Date & Estimatesmarketbeat.com
  4. 4Natera, Inc. Common Stock (NTRA) Earnings Reports & Dates | FXEmpirefxempire.com
  5. 5Natera, Inc. (NTRA) Analyst Ratings, Estimates & Forecasts - Yahoo Financefinance.yahoo.com
  6. 6NTRA | Natera Inc. Analyst Estimates | MarketWatchmarketwatch.com
  7. 7NTRA Q3 2026 earnings · hulicalendarhulicalendar.com
  8. 8NTRA Q3 2026 earnings · hulicalendarhulicalendar.com
  9. 9NTRA stock analysis — Natera — FrontierPicksfrontierpicks.com
  10. 10Natera (NTRA) Transcript: 2026 Global Healthcare Conferencestockanalysis.com

2. Price Chart

Historical Price (Probability)

Outcome probability
Date

3. Market Data

Contract Snapshot

This market resolves YES if Natera processed more than 1,075,000 tests in Q3, and NO if they processed 1,075,000 or fewer tests. Trading for this market ends on November 5 at 4:00 PM EST, with a maximum payout date of March 5, 2027. No special settlement conditions beyond the test count threshold are mentioned.

Market Discussion

As of October 24, 2026, the prediction market indicated probabilities of 99% for Natera processing over 1,025,000 tests and 95% for over 1,050,000 tests in Q3 2026 [1]. This appears to diverge from an AI market summary stating that management did not expect Q3 2026 volume to establish a new record, implying a result below Q2 2026's approximate 1,043,900 tests processed [2]. Broader social commentary was generally bullish on Natera's growth and margin improvement into Q3, despite noted risks like valuation and insider selling [3].

Sources (3)
  1. 1Natera tests processed in Q3 Odds & Predictions 2026kalshi.com
  2. 2Natera, Inc. | Natera Reports Second Quarter 2026 Financial Resultsinvestor.natera.com
  3. 3Natera Stock (NTRA) Opinions on Recent Price Surge | Quiver Quantitativequiverquant.com

4. What is the consensus among Wall Street analysts for Natera's Q3 2026 test volume, and how has this trended since the Q2 report?

Wall Street Analyst Consensus Q3 2026 Test VolumeApproximately 1.08 million tests [1][2]
Analyst Consensus Range Q3 20261.00 million–1.15 million tests [1][2]
Management Q2 2026 Baseline Tests1,043,900 total tests [2][3]
Wall Street analysts anticipate Natera's Q3 2026 test volume around 1.08 million tests. Consensus projections for Natera's third quarter 2026 test volume stand at approximately 1.08 million tests [1][2]. Since the Q2 report on August 6, expectations have largely coalesced around this figure, remaining consistently above 1.025 million but not exceeding 1.10 million [2]. The most explicit published analyst consensus data for Q3 2026 indicates a projected range of 1.00 million to 1.15 million tests, with the middle 50% falling between roughly 1.07 million and 1.10 million [1][2].
Management's outlook for Q3 volume tempered expectations after a record Q2. This projection aligns with management's previously communicated linear-growth framework and their caution against extrapolating the volume surge observed in Q2, which was significantly influenced by weather recovery [2]. Management noted that the Q2 2026 baseline of 1,043,900 total tests, a company record, saw its sequential increase driven by Q1 weather effects, and they did not foresee setting another volume record in Q3 [2][3].
A prediction market suggested Q3 volume near 1.075-1.10 million, with caveats. A prediction market indicated probabilities centered around 1.075 million to 1.10 million tests, implying a high likelihood of surpassing 1.025 million tests [4][5]. However, the reliability of this prediction market data is considered low. This is primarily due to a reported lack of executed contracts or significant trading activity, meaning its probabilities do not reflect a robust independent Wall Street consensus [6].
Sources (6)
  1. 1Natera, Inc. (NTRA) Stock Price, News & Chart | 4Conservative Finance4conservative.com
  2. 2Natera (NTRA) Q2 2026 Earnings Call Transcriptfool.com
  3. 3Natera Inc (NTRA) (Q2 2026) Earnings Call Highlightsfinance.yahoo.com
  4. 4Natera tests processed in Q3 Odds & Predictions 2026kalshi.com
  5. 5Natera tests processed in Q3 - Cuotas en Kalshi | CoinRithmcoinrithm.com
  6. 6Natera tests processed in Q3 - Kalshi Odds | CoinRithmcoinrithm.com

5. What specific evidence did Natera management provide to support their guidance against a new test volume record in Q3 2026?

Q2 2026 Record Test VolumeApproximately 1,043,900 processed tests [1][2][3]
Q3 2026 Test Volume OutlookNo new record anticipated [1][2][3]
2026 Revenue Guidance$2.85 billion-$2.91 billion [1][2][3]
Natera does not anticipate a new test volume record in Q3 2026. Despite robust performance in July, Natera management has indicated they do not expect to surpass the current record of approximately 1,043,900 tests, which was established in Q2 2026 [1][2][3].
Q2 Signatera volume growth was inflated, impacting Q3 record projections. The main reason for not forecasting a new record in Q3 2026 is linked to the analysis of Q2 Signatera volume growth, which management noted was artificially boosted by several thousand units. This inflation occurred because Q1 volumes had been negatively affected by adverse weather conditions [1][2][4]. As a result, the company's forecasting framework, which relies on a linear-growth model based on the average unit growth from the preceding four quarters, did not fully extrapolate this exaggerated Q1-to-Q2 increase into Q3. This methodology aims to smooth out random variations from factors like weather, seasonality, and receiving days, supporting continued growth but not necessarily a new record quarter [1][2][4].
Key average selling price drivers are not expected to boost Q3 volumes. Further supporting the guidance against a sharp Q3 acceleration is the timing of significant average selling price (ASP) drivers. Key factors such as expanded MolDX coverage, benefits from bladder-cancer NCCN guidelines, and additional indication guidelines are largely projected to impact results more significantly in 2027 and were specifically excluded from the 2026 guidance [1][2]. Although management did forecast meaningful second-half revenue growth and revised its overall 2026 revenue guidance upwards to $2.85 billion-$2.91 billion, attributing this to volume growth and stable ASPs, this was not a specific Q3 test-count projection [1][2][3].
Sources (4)
  1. 1Natera (NTRA) Q2 2026 Earnings Call Transcripttheglobeandmail.com
  2. 2Earnings call transcript: Natera tops revenue view in Q2...investing.com
  3. 3Natera Reports Second Quarter 2026 Financial Resultsbiospace.com
  4. 4Natera (NTRA) Q2 2026 Earnings Call Transcript and Summarygloom.sh

6. How might the new Medicare LCD for organ health tests, effective August 30, impact Natera's Q3 2026 volume compared to prior quarters?

Medicare LCD Effective DateAugust 30, 2026 [1][2][3][4]
Q2 2026 Test Volume1,043,900 tests [5][6]
Q3 2026 Volume Outlook1.02–1.05 million tests [5][6][2]
The new Medicare LCD will positively impact Natera's Prospera volumes. The new Medicare Local Coverage Determination (LCD) for solid-organ allograft rejection, effective August 30, 2026, is expected to improve Natera's Prospera testing volumes [1][2][3]. However, company management has indicated that Q3 2026 may not set a new sequential company volume record [1][2][3][7][4]. This suggests the LCD will act as a positive catalyst late in the quarter rather than providing a full-quarter volume step-up [1][2][3][7][4]. Specifically, the MolDX LCD covers Natera's Prospera surveillance testing for kidney, heart, and lung transplants at particular frequencies [1][4].
Natera anticipates modest Q3 2026 volume decline despite LCD benefits. Natera processed approximately 1,013,600 tests in Q1 2026 and a record 1,043,900 tests in Q2 2026 [5][6]. Management attributed some of the Q2 sequential growth to weather-related suppression experienced in Q1 [2][3]. Despite the new LCD, the central projection for Q3 2026 is a modest sequential decline from Q2, with an indicative range of roughly 1.02–1.05 million tests [5][6][2]. This outlook is influenced by factors such as only September being fully exposed to the effective date, potentially gradual changes in physician protocols, and existing limits allowing only one molecular service to be billed per patient encounter, with surveillance frequency limits still applying [1][7][4]. To achieve volumes greater than 1.05 million tests, stronger-than-expected Prospera uptake and continued growth in oncology and women's health segments would be necessary [5][6][2].
Sources (7)
  1. 1LCD - MolDX: Molecular Testing for Solid Organ Allograft Rejection (L40249)cms.gov
  2. 2Natera (NTRA) Q2 2026 Earnings Call Transcriptfool.com
  3. 3Natera (NTRA) Q2 2026 Earnings Call Transcript & Audiostockanalysis.com
  4. 4Finalized MolDx LCD Includes Expanded Coverage for...natera.com
  5. 5Natera, Inc. | Natera Reports Second Quarter 2026 Financial Resultsinvestor.natera.com
  6. 6Natera, Inc. | Natera Reports First Quarter 2026 Financial Resultsinvestor.natera.com
  7. 7Article - Billing and Coding: MolDX: Molecular Testing for Solid Organ Allograft Rejection (A60152)cms.gov

7. How does the projected Q3 2026 volume growth in Natera's Oncology (Signatera) segment compare to its Women's Health segment?

Q3 2026 Oncology/Signatera GrowthExpected to grow materially faster than Women's Health [1][2]
Q3 2026 Women's Health GrowthExpected to continue positive, high-single-digit growth [1][2]
Q3 2026 Volume Record ExpectationNot expected to set a new company volume record [3][1]
Natera's Oncology (Signatera) segment is projected to experience materially faster volume growth in percentage terms for Q3 2026 compared to its Women's Health segment [1][2]. Clinical oncology volume, particularly for Signatera, is anticipated to continue growing in Q3 2026, building on a linear model based on average unit growth from the prior four quarters, and was identified as the faster-growing segment entering Q3 [1][2][4][5]. In Q2 2026, oncology tests reached approximately 296,700, reflecting a 57.2% year-over-year increase, with clinical MRD units at about 283,000, up approximately 56% year-over-year [5][4]. A precise Q3 percentage forecast, however, was not provided for either segment [1][2].
Women's Health forecasts positive, high-single-digit Q3 2026 growth. Management indicated that Natera's Women's Health segment is expected to maintain positive, high-single-digit growth during this period, with overall growth projected to be more moderate [1][2][6]. This aligns with Q2 2026 performance, which delivered high-single-digit year-over-year growth even though it is typically the softest seasonal quarter for the segment [2][6]. Management attributed this growth to successful new-account wins, increased Fetal Focus adoption, and the launch of enhanced Panorama offerings [2][6]. Despite expectations for continued growth in Q3, management clarified that this quarter is not anticipated to set a new company volume record [3][1].
Sources (6)
  1. 1Natera (NTRA) Q2 2026 Earnings Call Transcript & Audiostockanalysis.com
  2. 2Natera (NTRA) Q2 2026 Earnings Call Transcriptfool.com
  3. 3Natera tests processed in Q3 Odds & Predictions 2026kalshi.com
  4. 4Natera Reports Second Quarter 2026 Financial Resultsinvestor.natera.com
  5. 5Natera Reports Second Quarter 2026 Financial Resultsbiospace.com
  6. 6Natera Inc (NTRA) (Q2 2026) Earnings Call Highlightsfinance.yahoo.com

8. What is the typical seasonal pattern for Natera's test volumes between Q2 and Q3 based on data from 2023-2025?

Average Q2-Q3 Increase (2023-2025)21,600 tests (+2.7%) [1][2][3][4]
2025 Q2-Q3 Increase40,500 tests (+4.7%) [3][4]
Q3 2025 Total Tests Processed893,600 tests [5][4][6]
Natera's test volumes consistently increase from Q2 to Q3. Natera's test volumes consistently increase from the second quarter (Q2) to the third quarter (Q3) based on data from 2023 to 2025 [1][2][3][4]. Across these three years, the sequential increase in Q3 volumes averaged approximately 21,600 tests, representing a 2.7% rise over Q2 [1][2][3][4].
Specific annual data reveals varying Q2 to Q3 increases. Specific annual data for this period shows increases of 8,800 tests (+1.4%) in 2023, rising from 617,200 in Q2 to 626,000 in Q3, and 15,500 tests (+2.0%) in 2024, from 760,300 in Q2 to 775,800 in Q3 [1][2]. In 2025, the increase was approximately 40,500 tests (+4.7%), moving from 853,100 in Q2 to 893,600 in Q3 [3][4]. Natera management has acknowledged this recurring Q2 seasonality, noting that winning new accounts helps mitigate the effect [7]. The substantial 2025 Q2-to-Q3 increase was notably amplified by momentum in oncology and minimal residual disease (MRD) testing, including a record sequential growth of about 21,500 clinical MRD units, suggesting this particular step-up might exceed a typical seasonal effect [4][3].
The consistent pattern informs future volume expectations. The consistent Q2-to-Q3 pattern observed from 2023-2025 provides a directional expectation of higher Q3 volumes compared to Q2; however, it does not establish a precise threshold for the 2026 prediction market outcome for Q3 total tests processed [8][9]. The most recent historical benchmark for this trend is 893,600 tests processed in Q3 2025 [5][4][6].
Sources (9)
  1. 1Natera Reports Second Quarter 2024 Financial Results | Nateranatera.com
  2. 2Natera, Inc. | Natera Reports Third Quarter 2023 Financial Resultsinvestor.natera.com
  3. 3Natera, Inc. | Natera Reports Second Quarter 2025 Financial Resultsinvestor.natera.com
  4. 4Natera, Inc. | Natera Reports Third Quarter 2025 Financial Resultsinvestor.natera.com
  5. 5Natera Reports Third Quarter 2025 Financial Results | Nateranatera.com
  6. 6Natera, Inc. | Natera Reports Third Quarter 2025 Financial Resultsinvestor.natera.com
  7. 7Natera NTRA Q2 2025 Earnings Call Transcriptfool.com
  8. 8Natera tests processed in Q3 Odds & Predictions 2026kalshi.com
  9. 9Natera tests processed in Q3 - Kalshi Odds | CoinRithmcoinrithm.com

9. What Could Change the Odds

Key Catalysts

Q3 test volume represents a primary catalyst. Kalshi prices Natera Q3 2026 processed tests above 1,025,000 at 99%, above 1,050,000 at 95%, above 1,075,000 at 69%, and above 1,100,000 at 25% [1][2]. The market anticipates processed tests between approximately 1.025M and 1.075M, noting Q2 2026 was a record 1,043,900 tests and management reportedly cautioned Q3 might not set another record [2]. A Q3 volume exceeding 1.10M tests would be a strong bullish surprise, while a result below 1.025M tests would constitute a bearish miss [1][2][3]. Street Q3 2026 revenue estimates range from $707.6M to $719.0M, with EPS around a $0.27–$0.28 loss [3][4][5]. The actionable Q3 earnings event window is November 5–11, though Natera had not yet definitively announced the date [6][5][7].
Potential bullish catalysts include continued Signatera and MRD volume growth, expanded payer coverage and guideline inclusion, and the August 30 organ-health Medicare coverage change [8][9][10]. Enhanced Panorama and Fetal Focus, Japan commercialization, and prospective-study readouts also present upside potential [8][9][10]. Future MolDX decisions could further lift Signatera ASP, which was approximately $1,275 and expected stable through year-end [2][8][9][10].
Key risks include Q3 volume failing to exceed the Q2 record, revenue true-up volatility, and persistent operating losses with high investment spending [2][4][8][10]. Accounts receivable growing faster than revenue, stable rather than rising near-term ASP, and execution or timing risk around reimbursement and clinical approvals also pose challenges [4][8][10]. Investors should monitor processed tests, oncology and clinical-MRD units, tests reported, revenue excluding prior-period true-ups, Signatera ASP, gross margin, operating loss/expense growth, cash flow, and accounts receivable [2][8].

Key Dates & Catalysts

  • Expiration: March 05, 2027
  • Closes: March 05, 2027
Sources (10)
  1. 1Natera tests processed in Q3 Odds & Predictions 2026kalshi.com
  2. 2Natera, Inc. | Natera Reports Second Quarter 2026 Financial Resultsinvestor.natera.com
  3. 3Natera, Inc. (NTRA) Analyst Ratings, Estimates & Forecasts - Yahoo Financefinance.yahoo.com
  4. 4Natera (NTRA) Q2 2026 Earnings Recap: Record Test Volumes and a $100 Million Guidance Boosttickeron.com
  5. 5Natera, Inc. Common Stock (NTRA) Earnings Reports & Dates | FXEmpirefxempire.com
  6. 6Natera (NTRA) Investor Relations, Earnings Summary & Outlookquartr.com
  7. 7NTRA Q3 2026 earnings · hulicalendarhulicalendar.com
  8. 8Earnings call transcript: Natera tops revenue view in Q2 2026, shares jump after hours By Investing.cominvesting.com
  9. 95 Insightful Analyst Questions From Natera’s Q2 Earnings Callfinance.yahoo.com
  10. 10Natera (NTRA) FY 2026 Earnings Call Transcript & Audiostockanalysis.com